端粒酶逆转录酶(TERT)启动子突变检测的分析验证
该研究对Afirma TERT启动子突变检测进行解析验证,评估DNA输入量、检测限、阴阳性符合率、分析特异性及重复性。结果显示该检测耐受7-13 ng DNA输入,在7 ng DNA输入下可检出低至5% VAF的预期阳性变异,灵敏度大于95%,阴阳性符合率均为100%,在20% RNA或80%血液gDNA存在下仍准确,外部实验室NGS参考方法确认率100%。
要点
- Afirma TERT检测耐受7-13 ng DNA输入量。
- 7 ng DNA输入下检测限为5% VAF,灵敏度大于95%。
- 阴阳性符合率均为100%,外部NGS参考方法确认率100%。
核心结论
- Afirma TERT检测的分析稳健性和重复性支持其在Afirma基因组测序分类器可疑的不确定细胞学甲状腺结节或Bethesda V/VI结节中常规临床使用。
研究设计与样本
- 对Afirma TERT启动子突变检测进行解析验证,分析基因组DNA中TERT启动子C228T和C250T变异检测,评估可变DNA输入量和变异等位基因频率检测限。
- 检测阴阳性符合率与参考引物对比较,分析RNA和血液gDNA潜在干扰物质的分析特异性,并测试批内、批间和实验室间重复性。
主要发现
- Afirma TERT检测耐受DNA输入量7-13 ng的变化。
- 在7 ng DNA输入下可检出预期阳性TERT启动子变异低至5% VAF检测限,灵敏度大于95%。
- 阴阳性符合率与参考引物对比较均为100%。
- 在20% RNA或80%血液gDNA存在下,对平均VAF为30%的典型患者样本检测仍准确。
- 与在非Veracyte实验室执行的外部下一代测序参考方法比较,确认率为100%。
临床怎么用
- Afirma TERT检测的分析稳健性和重复性支持其在Afirma基因组测序分类器可疑的不确定细胞学甲状腺结节或Bethesda V/VI结节中常规临床使用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Telomerase reverse transcriptase (TERT) promoter-mutated thyroid cancers are associated with a decreased rate of disease-free and disease-specific survival. High-quality analytical validation of a diagnostic test promotes confidence in the results that inform clinical decision-making. OBJECTIVE: This work aimed to demonstrate the analytical validation of the Afirma TERT promoter mutation assay. METHODS: TERT promoter C228T and C250T variant detection in genomic DNA (gDNA) was analyzed by assessing variable DNA input and the limit of detection (LOD) of variant allele frequency (VAF). The negative and positive percentage agreement (NPA and PPA) of the Afirma TERT test was examined against a reference primer pair as was the analytical specificity from potential interfering substances (RNA and blood gDNA). Further, the intrarun, interrun, and interlaboratory reproducibility of the assay were tested. RESULTS: The Afirma TERT test is tolerant to variation in DNA input amount (7-13 ng) and can detect expected positive TERT promoter variants down to 5% VAF LOD at 7 ng DNA input with greater than 95% sensitivity. Both NPA and PPA were 100% against the reference primer pair. The test remains accurate in the presence of 20% RNA or 80% blood gDNA for an average patient sample that typically has 30% VAF. The test also demonstrated a 100% confirmation rate when compared with an external next-generation sequencing-based reference assay executed in a non-Veracyte laboratory. CONCLUSION: The analytical robustness and reproducibility of the Afirma TERT test support its routine clinical use among thyroid nodules with indeterminate cytology that are Afirma Genomic Sequencing Classifier suspicious or among Bethesda V/VI nodules.
引用
- Iyer PC, Dadu R, Barque A, et al. Analytical Validation of a Telomerase Reverse Transcriptase (TERT) Promoter Mutation Assay. J Clin Endocrinol Metab. 2024. PMID: 38441247. doi:10.1210/clinem/dgae134
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。